ALK and non-small cell lung carcinoma: In addition, tumor growth suppression and survival rates were improved substantially in both orthotopic RDAA NSCLC cell line-derived and patient-derived xenograft tumor models following ALK inhibitor (crizotinib or ceritinib) treatment.